2 ultrasound AI systems cleared for market

The FDA has approved an AI tool for speeding thyroid sonography workflows while, across the big pond, the European Union has OK’d an AI-based ultrasound device that guides nerve blocking as a form of local anesthesia.

Edmonton-based Medo announced the U.S. go-ahead for its Medo-Thyroid May 6. The product uses algorithms to automatically review scans of the thyroid gland, calculating relevant measurements and classifying any nodules with the American College of Radiology’s TI-RADS system.  

The company says the product breaks new technological ground with various features, including a module for cross-referencing exams from various imaging modalities.

Meanwhile U.K.-based Intelligent Ultrasound Group earned CE Mark status in April for its ScanNav PNB, which supports nine common peripheral nerve blocks.

The company says the product plugs in to anesthesiology ultrasound machines and will be sold as a standalone device with embedded AI software.

Intelligent Ultrasound also says it’s currently working toward FDA approval and will seek to integrate ScanNav in ultrasound machines from various manufacturers.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.